GSK Investigational Site
Nottingham, NG11 6JS, United Kingdom
NCT Number: NCT06506266
The main goal of the study is to assess the effect of the administration of reference propellant [HFA-134a (1,1,1,2 - Tetrafluoroethane)] and test propellant [HFA-152a (1 - Difluoroethane)] in healthy adults on mucociliary clearance (MCC).
Looking for future studies?
Notify Me30 year–55 year
All sexes
Interventional
Phase 1
Nottingham, NG11 6JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants are eligible to be included in the study only if all following criteria apply:
Exclusion criteria
Participants who meet any of the following exclusion criteria at screening will not be eligible to participate in the study:
HFA-152a is administered via oral inhalation
HFA-134a is administered via oral inhalation
Radiolabeled saline solution is administered via oral inhalation
Time frame: At 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, and 240 minutes on Day 7
[AUC(0-4h)] was assessed for Mucociliary clearance (MCC) in participants following administration of nebulized 99mTc on Day 7. Gamma scintigraphy was utilized to conduct assessments.
Time frame: 1 hour after inhalation on Day 7
Gamma scintigraphy was utilized to conduct assessments.
Time frame: 1.5 hours after inhalation on Day 7
Gamma scintigraphy was utilized to conduct assessments.
Time frame: 3 hours after inhalation on Day 7
Gamma scintigraphy was utilized to conduct assessments.
Time frame: Up to approximately 13 weeks
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect, abnormal pregnancy outcomes. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. The AE data presented below is of frequency threshold - 0%.
GlaxoSmithKline
Industry
A Randomized, Double-blind, Single-site, Two-way Crossover Phase 1 Study to Assess the Effect of Repeated Doses of Test Propellant (HFA-152a) on Mucociliary Clearance as Compared to Reference Propellant (HFA-134a) in Healthy Male and Female Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial DetailsNCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT03937804
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial Details